ATNF 180lifesciences.com: Net earnings per share growth forecast for next year

ETHZilla Corporation (ATNF) developed treatments for arthritis and fibrosis via an anti-TNF platform. The business is currently undergoing a global transformation, completely shifting its market vector from biotech to crypto assets. The new strategy relies on B2B services and blockchain solutions to minimize regulatory risks. Analyst expectations for N+1 profit dynamics demonstrate volatile forecasts, where 0.00 describes the current status of the metric.
ETHZilla - analytical breakdowns and key metrics (ATNF)

The investment attractiveness of ETHZilla Corporation (ATNF) depends on the success of a radical pivot toward blockchain gaming amid a complete absence of current revenue. This indicator measures expected earnings per share (EPS) dynamics via analyst consensus forecasts, neutralizing reporting time lags. Analyzing the consensus EPS growth for the coming year allows for an assessment of the probability of overcoming the capital crisis and the fundamental viability of the new strategy.